SCHEMBL3547235

SCHEMBL3547235

Cc1ccc(-c2oncc2C(=O)N2CCc3ccccc3C2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
PLA2G1B P04054 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61
PDE4B Q07343 1/20 0.57
PDE4D Q08499 1/20 0.57
HPGD P15428 6/20 0.55
ALDH1A1 P00352 5/20 0.55
HTT P42858 4/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
TSHR P16473 2/20 0.52
KDM4E B2RXH2 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
BCL2 P10415 1/20 0.50
BAD Q92934 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TAS1R3 Q7RTX0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3552122 0.92 HCRTR1 (0.50) MAPTPLA2G1BATG4BPDE4BPDE4D
SCHEMBL3543135 0.84 ABCB1 (0.55) MAPTPDE4BHPGDALDH1A1KDM4E
SCHEMBL3544377 0.84 SPR (0.51) MAPTPLA2G1BATG4BPDE4BPDE4D
SCHEMBL3186687 0.80 ALDH1A1 (0.54) HPGDALDH1A1TSHRKDM4ENPSR1
SCHEMBL13501701 0.80 HPGD (0.62) MAPTPDE4BHPGDALDH1A1HTT
SCHEMBL3548124 0.78 MEN1 (0.53) MAPTALDH1A1HTTTSHRKDM4E
SCHEMBL3540470 0.78 ALDH1A1 (0.42) MAPTPLA2G1BATG4BPDE4BPDE4D
SCHEMBL3549217 0.77 KMT2A (0.46) HPGDALDH1A1TSHRNPC1RAB9A
SCHEMBL3553078 0.76 HCRTR1 (0.53) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL3549632 0.76 ALDH1A1 (0.50) HPGDALDH1A1HTTTSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 MAPT 3715/4885PLA2G1B 4324/4885ATG4B 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.